Gemphire Therapeutics (GEMP) is Initiated by Laidlaw to Buy, Price Target at $20

Gemphire Therapeutics (GEMP) was Initiated by Laidlaw to “Buy” and the brokerage firm has set the Price Target at $20. Laidlaw advised their investors in a research report released on Sep 6, 2016.

Many Wall Street Analysts have commented on Gemphire Therapeutics. RBC Capital Mkts Initiated Gemphire Therapeutics on Aug 30, 2016 to “Outperform”, Price Target of the shares are set at $25.Jefferies Initiated Gemphire Therapeutics on Aug 30, 2016 to “Buy”, Price Target of the shares are set at $15.

Gemphire Therapeutics

Leave a Reply

Gemphire Therapeutics - Is it time to Sell?

Top Brokerage Firms are advising their investors on Gemphire Therapeutics. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.